GlobeNewswire

TGS Capital Markets Day – Presentation and Webcast

Share

OSLO, Norway (9 February January 2021) – Further to the announcement on 21 January 2021, TGS will host its Capital Markets Day on 11 February 2021.

CEO Kristian Johansen and CFO Fredrik Amundsen will present the Q4 2020 results and 2021 guidance during the live-streamed event.

The Capital Markets Day will commence at CET 14.00 on 11 February 2021 and last until approximately CET 16.00. We encourage attendees to join the webcast 5-10 minutes before CET 14:00 to ensure access. During the webcast, there will be two opportunities for attendees to ask questions.

Presentation and webcast details:

An on-demand version of the Capital Markets Day will be available on TGS.com after the event.

For more information, visit TGS.com or contact:

Fredrik Amundsen, CFO
Tel.: +47 995 89 882
E-mail: investor@tgs.com

About TGS
TGS provides multi-client geoscience data to oil and gas Exploration and Production companies worldwide. In addition to extensive global geophysical and geological data libraries that include multi-client seismic data, magnetic and gravity data, digital well logs, production data and directional surveys, TGS also offers advanced processing and imaging services, interpretation products, and data integration solutions.

Forward Looking Statement
All statements in this press release other than statements of historical fact are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. These factors include TGS' reliance on a cyclical industry and principal customers, TGS' ability to continue to expand markets for licensing of data, and TGS' ability to acquire and process data product at costs commensurate with profitability, as well as volatile market conditions, which have been exacerbated by the COVID-19 pandemic and the severe drop in oil prices.  Actual results may differ materially from those expected or projected in the forward-looking statements. TGS undertakes no responsibility or obligation to update or alter forward-looking statements for any reason.


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Saniona får återkoppling från FDA gällande den regulatoriska vägen framåt för Tesomet mot hypotalamisk fetma8.3.2021 14:00:00 CETPressemelding

PRESSMEDDELANDE 8 mars 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att det amerikanska läkemedelsverket FDA lämnat återkoppling som ytterligare klarlägger det regulatoriska spåret för Tesomet som behandling av hypotalamisk fetma (HO). Baserat på den erhållna återkopplingen går Saniona vidare med planerna att inleda en fas 2b-studie på HO under första halvåret innevarande år. ”I dagsläget finns inga godkända mediciner för hypotalamisk fetma, en sällsynt sjukdom sekundär till skador i hypotalamus. Sjukdomen kännetecknas av svårhanterlig viktuppgång och kompliceras av okontrollerbar hunger”, säger Rudolf Baumgartner, Sanionas Chief Medical Officer och Head of Clinical Development. ”Återkopplingen från FDA är uppmuntrande, och vi ser fram emot att fortsätta den konstruktiva dialogen med myndigheten medan vi förbereder starten av vår kliniska fas 2b-studie med Tesomet.” Som Saniona tidigare meddelat har FDA

Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity8.3.2021 14:00:00 CETPress release

PRESS RELEASE March 8, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it received feedback from the U.S. Food and Drug Administration (FDA) providing further clarity on a regulatory path for Tesomet in the treatment of hypothalamic obesity (HO). Based on this feedback, Saniona is proceeding with plans to initiate a Phase 2b study in HO in the first half of this year. “There is currently no medicine approved for hypothalamic obesity, a rare disease secondary to hypothalamic injury, characterized by intractable weight gain and complicated by uncontrollable hunger,” said Rudolf Baumgartner, M.D., Chief Medical Officer and Head of Clinical Development at Saniona. “We are encouraged by this feedback from the FDA and look forward to continuing a constructive dialogue with them as we prepare to initiate our Phase 2b clinical trial with Tesomet.” Saniona previously announced that the FDA had highlighted the potential for off-lab

Signify share repurchase periodic update8.3.2021 13:00:00 CETPress release

Press Release March 8, 2021 Signify share repurchase periodic update Eindhoven, the Netherlands –Signify (Euronext: LIGHT), the world leader in lighting, today announced that it has repurchased 160,815 shares in the period March 1 to March 5, 2021. The shares were repurchased at an average price of EUR 36,64 per share and an aggregate amount of EUR 5.9 million. These repurchases were made as part of the company’s repurchase program, which was announced on February 25, 2021. Signify will use the shares to cover obligations arising from its long-term incentive performance share plan and other employee share plans. The total number of shares repurchased under this program to date is 216,690 shares for a total consideration of EUR 7.9 million. Details on the share buyback transactions can be found here. --- END --- For further information, please contact: Signify Investor Relations Thelke Gerdes Tel: +31 6 1801 7131 E-mail: thelke.gerdes@signify.com Signify Corporate Communications Elco va

PRFoods Ltd Swedish subsidiary landed major victory in court, increases fish farming capacity. PRFoods signes bridge financing agreement with major shareholder.8.3.2021 12:53:52 CETPress release

Överumans Fisk AB, fully owned subsidiary of PRFoods, was issued in 2020 additional licence in Gaskeloukti, Västerbotten county, Sweden. Licence gave right to use 2400 tons of feed which would give output of 2200 tons of fish. Licence was challenged by local residents and Överumans Fisk AB itself to gain additional feed tonnage. Land and Environmental Court issued a verdict not to accept the challenge by local residents. Överumans Fisk AB complaint was fully accepted and feed amount was increased to 3600 tons. Verdict is valid (it may be challenged in Supreme Court, but it will not stop the validity of the permit) and Överumans Fisk AB can utilize the new permit already in 2020 and the company has started already necessary investments for increased feed amount. Gaskeloukti site requires investments in the amount of 2,5 million euros. New permit will allow Överumans Fisk to increase from 2022 or 2023 its sales compared to last years by 3,5 times and depending on fish prices will give ad

Enento Group Plc’s Notice to the Annual General Meeting8.3.2021 12:00:00 CETPress release

ENENTO GROUP PLC, STOCK EXCHANGE RELEASE ON 8 MARCH 2021 AT 1.00 P.M. EET Enento Group Plc’s Notice to the Annual General Meeting Notice is given to the shareholders of Enento Group Plc ("Enento" or the "Company") to the Annual General Meeting to be held on Monday 29 March 2021 starting at 10:00 a.m. (EET) at Rantatie Business Park, Tutka & Plotteri Meeting Room (Hermannin rantatie 8, Main entrance: Verkkosaarenkatu 5, 00580 Helsinki, Finland). The Company’s Board of Directors has resolved on exceptional meeting procedures based on the temporary legislative act to limit the spread of the Covid-19 pandemic (677/2020), which entered into force on 3 October 2020. In order to ensure the health and safety of the shareholders, employees and other stakeholders of the Company, the Annual General Meeting will be organized without shareholders’ and their proxy representatives’ presence at the Annual General Meeting venue. Shareholders can participate in the Annual General Meeting and use their s

algoWatt will coordinate the GeTUP project for sustainable mobility as-a-service in urban areas8.3.2021 11:30:57 CETPress release

algoWatt will coordinate the GeTUP project for sustainable mobility as-a-service in urban areas Total funding of EUR 1 million for a low environmental impact, customised and accessible travel planning solutionThe company leads a partnership with Genoa's public transport operator, 5 SMEs and some research bodies algoWatt S.p.A. a GreenTech Solutions Company listed on the Italian Stock Exchange (MTA), will coordinate the GeTUP research project on sustainable mobility and MaaS (mobility as a service) solutions in the urban environment. The GeTUP project, worth a total of Euro 2 million, has received funding of Euro 1 million from the POR FESR 2014-2020 - Axis 1 - Action 1.2.4 - Poles of Research and Innovation of the Liguria Region, following approval by Finanziaria Ligure per lo Sviluppo Economico - FI.L.S.E. S.p.A., a technical entity that supports and assists the Liguria Region and other Ligurian territorial entities in the design, definition and implementation of policies and interven

Nexstim Abp:s företrädesemission av 6,6 miljoner euro8.3.2021 11:05:00 CETPressemelding

Företagsmeddelande, insiderinformation, Helsingfors den 8 mars 2021 kl. 12.05 (EET) Nexstim Abp:s företrädesemission av 6,6 miljoner euro FÅR EJ PUBLICERAS ELLER SPRIDAS DIREKT ELLER INDIREKT I FÖRENTA STATERNA, AUSTRALIEN, SYDAFRIKA , HONGKONG, JAPAN, CANADA, NYA ZEELAND, SINGAPORE ELLER NÅGON ANNAN STAT DÄR SPRIDNINGEN ELLER PUBLICERINGEN STRIDER MOT LAGEN Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolag”) meddelar att med bemyndigande av bolagets extra bolagsstämma den 1 mars 2021, har styrelsen idag fattat beslut om en företrädesemission av cirka 6,6 miljoner euro ("emissionen”). Kort om emissionen Nexstim:s nyemission av cirka 6,6 miljoner euro där rätten att teckna högst 219 811 378 aktier ("emissionaktierna") ska med företrädesrätt tillkomma bolagets aktieägare.Varje aktieägare i Nexstim tilldelas en (1) företrädesrätt som kontoförda värdepapper ("teckningsrätt"), per varje aktie i respektive ägares innehav på avstämningsdagen för emissionen den 10 mars 2021 ("avstämni